We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

36 hedge funds and large institutions have $1.56M invested in Carisma Therapeutics in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less funds holding

Funds holding: 37 → 36 (-1)

3.82% less ownership

Funds ownership: 13.36% → 9.53% (-3.8%)

10% less capital invested

Capital invested by funds: $1.73M → $1.56M (-$171K)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

Holders
36
Holders Change
-1
Holders Change %
-2.7%
% of All Funds
0.47%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
5
Increased
4
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$40.4K
2
Renaissance Technologies
Renaissance Technologies
New York
+$20.2K
3
GS
GTS Securities
New York
+$13.4K
4
UBS Group
UBS Group
Switzerland
+$5.09K
5
BBA
Baader Bank Aktiengesellschaft
Germany
+$4.92K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$280K
2
Barclays
Barclays
United Kingdom
-$147K
3
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft
Germany
-$62K
4
BlackRock
BlackRock
New York
-$18.8K
5
SWP
Stratos Wealth Partners
Ohio
-$6.88K
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
26
IFP Advisors
Florida
$81 – – –
OP
27
ORG Partners
Indiana
$80 – – –
CWA
28
Carolina Wealth Advisors
South Carolina
$59 – – –
Osaic Holdings
29
Osaic Holdings
Arizona
$55 – – –
SS
30
SBI Securities
Japan
$52 – -1 -0.8%
Barclays
31
Barclays
United Kingdom
$39 -$147K -549,205 -100%
MWA
32
Medallion Wealth Advisors
Connecticut
$39 – – –
Raymond James Financial
33
Raymond James Financial
Florida
$29 +$20 +75 New
National Bank of Canada
34
National Bank of Canada
Quebec, Canada
$20 – – –
HI
35
Harbour Investments
Wisconsin
$14 – – –
Jones Financial Companies
36
Jones Financial Companies
Missouri
$6 – – –
Universal-Beteiligungs- und Servicegesellschaft
37
Universal-Beteiligungs- und Servicegesellschaft
Germany
– -$62K -200,000 Closed
SWP
38
Stratos Wealth Partners
Ohio
– -$6.88K -22,200 Closed
LPL Financial
39
LPL Financial
California
– -$6.48K -20,895 Closed
SG
40
StoneX Group
New York
– -$3.33K -10,732 Closed
Federated Hermes
41
Federated Hermes
Pennsylvania
– -$1.75K -5,629 Closed
PBK
42
Peoples Bank (Kansas)
Kansas
– -$77 -250 Closed
1
2

CARM Hedge Fund Activity: Q2 2025 in Review

36 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2025, worth a combined $1.56M — down 9.9% from $1.73M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CARM and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 4 added.

The largest buyer was Jane Street, opening a new position worth an estimated $40.4K. The largest seller was Vanguard Group, cutting an estimated $280K.

  • 36 institutional investors held Carisma Therapeutics (CARM) as of Q2 2025, down from 37 in Q1 2025.
  • Funds reported $1.56M of Carisma Therapeutics stock for Q2 2025, down 9.9% quarter-over-quarter.
  • 5 funds opened new Carisma Therapeutics positions in Q2 2025 and 6 closed out, a net change of -1 holder.
  • The largest Carisma Therapeutics buyer in Q2 2025 was Jane Street, an estimated $40.4K added.
  • The largest Carisma Therapeutics seller in Q2 2025 was Vanguard Group, an estimated $280K sold.

Based on aggregated 13F filings for Q2 2025.